The Adherence to Hormonal Deprivation Therapy for Prostate Cancer in a Real Life Contest: Retrospective, Single-Centre Study

Aliberti A, Bada M, Rapisarda S, Natoli C, Schips L and Cindolo L

Department of Urology, S Pio da Pietrelcina Hospital, Via San Camillo de Lellis, Italy

^*Correspondance to: Cindolo L 

 PDF  Full Text Research Article | Open Access

Abstract:

Introduction and
Objectives: The Androgen Deprivation Therapy (ADT) is one of the therapeutic options for the treatment of prostate cancer (PCA), both for the advanced forms and metastatic forms, in a neoadjuvant or adjuvant setting, alone or in combination with surgery or radiotherapy (RT). Aim of the study is to appraise the adherence to the ADT.Material and
Methods: Patients with diagnosis of PCA, for which an ADT (leuprorelin, triptorelin or degarelix) has been prescribed, have been followed between January 2008 to December 2015. Demographic, histopathological and clinical data were collected.Results: 136 patients (mean age 76y and PSA 91.9 ng/ml) were followed over time. At diagnosis, 34% had a Gleason Score >7; 108 patients were exclusively treated by ADT: the drugs were prescribed as follow: 49% leuprorelin, 42% triptorelin, 9% degarelix. The mean follow-up was 3.5y, with a mean years of prescription of 3.4. Therefore the adherence was 98%. Of the 108 patients available for the analysis, 63 are currently treated by ADT, while 45 have stopped. The causes for discontinuation were: death, physician’s choice and patient’s preference in 56%, 33% and 11% of the cases, respectively.Conclusions: Today we have little and rarely data the data on patient’s adherence to ADT in the literature. On the basis of our results we highlight an adherence to the ADT close to 100%: it’s a regimen with high adherence.

Keywords:

Prostate cancer; Androgen deprivation therapy; Adherence

Cite the Article:

Aliberti A, Bada M, Rapisarda S, Natoli C, Schips L, Cindolo L. The Adherence to Hormonal Deprivation Therapy for Prostate Cancer in a Real Life Contest: Retrospective, Single-Centre Study. Clin Oncol. 2017; 2: 1343.